Journal
CANCER LETTERS
Volume 227, Issue 1, Pages 9-23Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2004.11.015
Keywords
HER-2; ErbB-2; neu; receptor tyrosine kinase; kinase inhibitors; breast cancer
Categories
Ask authors/readers for more resources
Activation of intracellular mitogenic signal transduction pathways driven by the ErbB family of receptor tyrosine kinases has been implicated in a variety of cancers. Amongst these, the tumorigenic roles of the Epidermal Growth Factor receptor (EGFR) and HER-2 have been most extensively studied. Therapeutic antibodies and small molecule kinase inhibitors targeting EGFR have recently received regulatory agency approval for the treatment of colon and lung cancer, respectively. In this review, I briefly describe these agents and their potential use in inhibiting the growth of tumors that overexpress HER-2. I also discuss other therapeutics currently available or being developed specifically to target HER-2 dependent tumors. (C) 2004 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available